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Objectives. The purpose of this study was to evaluate the
importance of time to reperfusion for outcomes after primary
angioplasty for acute myocardial infarction.
Background. Survival benefit of thrombolytic therapy for acute
myocardial infarction is strongly dependent on time to treatment.
Recent observations suggest that time to treatment may be less
important for survival with primary angioplasty.
Methods. Consecutive patients (n 5 1,352) with acute myocar-
dial infarction treated with primary angioplasty were followed for
up to 13 years. Paired acute and follow-up ejection fraction data
were obtained at cardiac catheterization in 606 patients.
Results. Reperfusion was achieved within 2 h in 164 patients
(12%). Thirty-day mortality was lowest with early reperfusion
(4.3% at <2 h vs. 9.2% at >22 h, p 5 0.04) and was relatively
independent of time to reperfusion after 2 h (9.0% at 2 to 4 h, 9.3%
at 4 to 6 h, 9.5% at >6 h). Thirty-day–plus late cardiac mortality
was also lowest with early reperfusion (9.1% at <2 h vs. 16.3% at
>22 h, p 5 0.02) and relatively independent at time to reperfusion
after 2 h (16.4% at 2 to 4 h, 16.9% at 4 to 6 h, 15.6% at >6 h).
Improvement in left ventricular ejection fraction was greatest in
the early reperfusion group and relatively modest after 2 h (6.9%
at <2 h vs. 3.1% at >22 h, p 5 0.007).
Conclusions. Time to reperfusion, up to 2 h, is important for
survival and recovery of left ventricular function. After 2 h,
recovery of left ventricular function is modest and survival is
relatively independent of time to reperfusion. These data suggest
that factors other than myocardial salvage may be responsible for
survival benefit in patients treated with primary angioplasty after
2 h.
(J Am Coll Cardiol 1998;32:1312–9)
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Over the past decade the use of reperfusion therapy for acute
myocardial infarction has dramatically reduced mortality (1–
3). Thrombolytic therapy is thought to be beneficial when
coronary reperfusion can be established early enough to
salvage myocardium with consequent improvement in left
ventricular function and better survival. Data from a number
of randomized trials have shown that the mortality benefit of
thrombolytic therapy is strongly dependent on the time from
symptom onset until treatment (1,4–6). However, recent ob-
servations suggest that time to treatment may be less important
for survival after primary angioplasty (percutaneous translu-
minal coronary angioplasty [PTCA]) than after thrombolytic
therapy (7). The purpose of this study is to evaluate the
importance of time to reperfusion for 30-day and late survival
and recovery of left ventricular function after primary PTCA
for acute myocardial infarction.
Methods
Study population. The study population consisted of 1,352
consecutive patients with acute myocardial infarction treated
with primary PTCA without prior thrombolytic therapy by one
cardiology group at our institution from 1984 through 1996.
Patient selection criteria have been previously described (8).
Patients were selected for intervention if they presented with
chest pain of ,12 h duration (,6 h before 1992). Patients were
selected for intervention after 12 h (after 6 h before 1992) only
if they had persistent ischemic chest pain or hemodynamic
compromise. Patients were included in the study only if they
had a diagnostic electrocardiogram with ST-segment elevation
of $1 mm in $2 contiguous leads (or reciprocal ST-segment
depression of $1 mm in leads V1 and V2) or left bundle branch
block. Primary PTCA has been the preferred reperfusion
strategy at our institution since 1984. Of all patients with acute
myocardial infarction seen at our institution with diagnostic
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electrocardiograms during the study period, approximately
70% received primary PTCA, 10% thrombolytic therapy (usu-
ally given at a referring hospital prior to transfer) and 20%
received no reperfusion therapy usually because of late pre-
sentation, resolution of symptoms or comorbid disease (9).
Treatment protocol. The protocol for primary PTCA at
our institution has been previously described (8). Patients were
given 5,000 to 10,000 U of heparin intravenously and 325 mg
chewable aspirin in the emergency department and transferred
promptly to the catheterization laboratory. Reperfusion was
established mechanically with primary PTCA without anteced-
ent use of thrombolytic therapy. Adjunctive therapy with
temporary transvenous pacing or intraaortic balloon pumping
were performed at the discretion of the operator. Following
the procedure, heparin was continued for 2 to 3 days, adjusted
to prolong the activated partial thromboplastin time to 2 to 3
times the control value. Beta-adrenergic blocking agents and
nitrates were used at the discretion of the operator and became
standard treatment in the last 3 years of the study. Coronary
stents were used in 103 patients during the last 2 years of the
study. Treatment with the monoclonal antibody directed
against the platelet IIb/IIIa glycoprotein receptor (abciximab)
was used in 38 patients.
Clinical and angiographic follow-up. Clinical follow-up
was obtained by hospital and office chart review and telephone
contact. Follow-up catheterization and angiography were per-
formed routinely during the first 3 years of the study and
during participation in several clinical trials (the Primary
Angioplasty Registry in 1990 to 1991, the Second Primary
Angioplasty in Myocardial Infarction [PAMI-2] Trial in 1993
to 1994, the PAMI Stent Pilot Trial in 1995 to 1996 and the
Stent PAMI Randomized Trial in 1997) (10–12). Otherwise,
follow-up catheterization was performed for recurrent isch-
emic symptoms or after abnormal functional testing. Left
ventricular ejection fractions were calculated from tracing
contours of right anterior oblique cineangiograms using the
area–length method with correction for the right anterior
oblique projection (13).
Data analysis. Time to reperfusion was measured as the
time from the onset of symptoms until coronary reperfusion
was established with balloon inflation. If Thrombolysis In
Myocardial Infarction (TIMI)-3 flow was present on the initial
angiogram, the time of the initial angiogram was used as the
time of reperfusion. For the purpose of this analysis, time to
reperfusion was divided into four categories: ,2 h, 2 to ,4 h,
4 to ,6 h and $6 h. Coronary flow in the infarct artery after
primary PTCA was assessed visually by the operator and
classified according to the TIMI grading system on a scale of 0
to 3 (14). Cardiogenic shock was defined as hypotension
(systolic blood pressure ,85 mm Hg) not responsive to volume
expansion and associated with severe left ventricular dysfunc-
tion or right ventricular infarction.
Variables examined as predictors of 30-day survival and
30-day–plus late cardiac survival included age, gender, diabe-
tes, prior myocardial infarction, prior coronary bypass surgery,
cardiogenic shock before intervention, infarction location,
3-vessel coronary artery disease, acute left ventricular ejection
fraction, TIMI flow post intervention and reperfusion time.
Statistical comparisons of baseline, procedural and outcome
variables between subgroups were performed using the chi-
square statistic for categorical variables and Student’s unpaired
t test and analysis of variance for continuous variables. Multi-
ple logistic regression was used to assess the relation between
predictor variables and 30-day mortality. Differences in 30-
day–plus late cardiac survival across categories of discrete
predictor variables were examined with Kaplan–Meier survival
curves and their associated log-rank test statistics. Multivari-
able analyses of predictors of 30-day–plus late cardiac survival
were performed using Cox proportional hazards regression
models. All analyses were performed with SAS (SAS Institute
Inc., Cary, North Carolina) and SPSS (SPSS, Inc., Chicago,
Illinois) statistical software.
Results
Of 1,352 patients treated with primary PTCA for acute
myocardial infarction, 164 patients (12%) were reperfused
within 2 h, 581 patients (43%) within 2 to 4 h, 332 patients
(25%) within 4 to 6 h and 275 patients (20%) after 6 h. The
TIMI-3 flow was achieved in 1,248 patients (92.3%), TIMI-2
flow in 65 patients (4.8%) and TIMI-0-1 flow in 39 patients
(2.9%). Thirty-day mortality was 8.6% (116 patients). Clinical
follow-up was obtained in 1,222 of 1,238 30-day survivors
(98.7%) at a mean follow-up time of 5.0 6 3.4 years. There
were 93 (6.9%) late cardiac deaths.
Baseline characteristics by time to reperfusion. Baseline
variables for the four categories of time to reperfusion are
shown in Table 1. The proportion of women and the incidence
of diabetes were highest in the late reperfusion group (.6 h),
whereas the incidence of prior myocardial infarction and
anterior wall myocardial infarction was highest in the early
reperfusion group (,2 h). Acute ejection fraction was higher
in the early reperfusion group (,2 h) than in the three later
reperfusion groups combined ($2 h) (54.7 6 13% vs. 52.0 6
13%, p 5 0.02).
Relationship between time to reperfusion and TIMI flow
postintervention. The frequency of achieving TIMI-3 flow in
the infarct artery after primary PTCA was high (90 to 93%) in
each of the four categories of time to reperfusion and was
similar regardless of the time to reperfusion (Table 2).
Abbreviations and Acronyms
GUSTO 5 global utilization of streptokinase and tPA for occluded
coronary arteries
PAMI 5 primary angioplasty in myocardial infarction (trial)
PTCA 5 percutaneous transluminal coronary angioplasty
TIMI 5 Thrombolysis in Myocardial Infarction (trial)
tPA 5 tissue plasminogen activator
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Importance of time to reperfusion for 30-day mortality and
30-day–plus late cardiac mortality. Thirty-day mortality was
lowest in the early reperfusion group (4.3% at ,2 h vs. 9.2% at
$2 h, p 5 0.04) and was relatively independent of time to
reperfusion after 2 h (Table 2, Fig. 1). Late cardiac mortality
(.30 days) was lowest in the early reperfusion group (,2 h),
but this was not statistically different from the later reperfusion
groups (Table 2). Thirty-day–plus late cardiac mortality was
also lowest in the early reperfusion group (9.1% at ,2 h vs.
15.3% at $2 h, p 5 0.02) and was relatively independent of
time to reperfusion after 2 h (Table 2, Fig. 1).
When the effect of late reperfusion ($2 h) on 30-day
mortality was adjusted for differences in baseline variables with
multiple logistic regression, late reperfusion was a relatively
weak correlate of 30-day mortality (odds ratio [OR] 1.54, 95%
confidence interval [CI] 0.89 to 2.66, p 5 0.12) (Fig. 2). When
acute ejection fraction was excluded from the model (since
some patients had missing ejection fraction data), late reper-
fusion ($2 h) became a slightly stronger predictor of 30-day
mortality (OR 1.59, 95% CI 1.00 to 2.51, p 5 0.05). Cardio-
genic shock and the inability to restore TIMI-3 flow were the
strongest predictors of 30-day mortality (Fig. 2).
Kaplan–Meier survival curves of 30-day–plus late cardiac
survival for each of the four categories of time to reperfusion
are shown in Figure 3. Survival in the early reperfusion group
(,2 h) was significantly better than the three later reperfusion
Table 1. Baseline Variables Versus Time to Reperfusion
Time to Reperfusion
,2 H
(n 5 164)
(12%)
2–4 H
(n 5 581)
(43%)
4–6 H
(n 5 332)
(25%)
.6 H
(n 5 275)
(20%)
All Subjects
(n 5 1,352)
Baseline variable Number (%) p Value
Age .70 yrs 46 (28) 115 (20) 69 (21) 64 (23) 294 (22) 0.12
Age (yrs) (mean 6 SD) 60.8 6 12 58.8 6 12 60.4 6 12 59.8 6 12 59.6 6 12 0.11
Women 46 (28) 160 (28) 90 (27) 97 (35) 393 (29) 0.09
Diabetes 15 (9.1) 82 (14) 45 (14) 58 (21) 201 (15) 0.004
Prior MI 46 (28) 121 (21) 54 (16) 43 (16) 264 (20) 0.004
Prior CABG 5 (3.0) 27 (4.6) 24 (7.2) 7 (2.5) 63 (4.7) 0.03
Anterior MI 75 (46) 239 (41) 115 (35) 119 (43) 548 (41) 0.06
Cardiogenic shock* 10 (6.1) 48 (8.3) 30 (9.0) 27 (9.8) 115 (8.5) 0.57
3 Vessel CAD 36 (22) 120 (21) 77 (23) 60 (22) 293 (22) 0.84
Acute EF , 40%† 20 (14) 93 (18) 56 (19) 49 (19) 218 (18) 0.60
Acute EF (%)† (mean 6 SD) 54.7 6 13 52.4 6 14 51.7 6 13 51.3 6 13 52.3 6 13 0.90‡
*Cardiogenic shock occurring before intervention. †Includes data on 1,223 subjects. ‡Acute EF was higher in the early reperfusion group (,2 h) versus the three
later reperfusion groups combined ($2 h) (54.7 6 13 vs. 52.0 6 13, p 5 0.02).
Abbreviations: CABG 5 coronary artery bypass graft surgery; CAD 5 coronary artery disease; EF 5 ejection fraction; MI 5 myocardial infarction.
Table 2. TIMI Flow, Mortality and Ejection Fraction Versus Time to Reperfusion
Time to Reperfusion
,2 H
(n 5 164)
(12%)
2–4 H
(n 5 581)
(43%)
4–6 H
(n 5 332)
(25%)
.6 H
(n 5 275)
(20%)
All Subjects
(n 5 1,352)
Variable Number (%) p Value
TIMI-3 flow (postintervention) 148 (90.2) 542 (93.3) 304 (91.6) 254 (92.4) 1,248 (92.3) 0.57
30-day mortality 7 (4.3) 52 (9.0) 31 (9.3) 26 (9.5) 116 (8.6) 0.21†
Late cardiac mortality 8 (4.9) 43 (7.4) 25 (7.5) 17 (6.2) 93 (6.9) 0.36
30-day–plus late cardiac mortality 15 (9.1) 95 (16.4) 56 (16.9) 43 (15.6) 209 (15.5) 0.12‡
Acute EF (%)* 52.6 6 14 52.3 6 14 52.0 6 12 51.8 6 12 52.2 6 13 0.98
Late EF (%) improvement 59.5 6 14 54.8 6 14 55.7 6 14 55.8 6 12 55.7 6 13 0.08§
EF (%) 6.9 6 11 2.5 6 12 3.7 6 11 3.9 6 11 3.6 6 12 0.04\
*Ejection fraction data include only subjects with paired acute and late ejection fractions (n 5 606) and is expressed as mean 6 SD. †Thirty-day mortality was
significantly lower in the early reperfusion group (,2 h) versus the three later reperfusion groups combined ($2 h) (4.3% vs. 9.2%, p 5 0.04). ‡Thirty-day–plus late
cardiac mortality was significantly lower in the early reperfusion group (,2 h) versus the three later reperfusion groups combined ($2 h) (9.1% vs. 16.3%, p 5 0.02).
§Late EF was significantly higher in the early reperfusion group (,2 h) versus the three later reperfusion groups combined ($2 h) (59.5 6 14% vs. 55.3 6 13%, p 5
0.02). \Improvement in EF was greater in the early reperfusion group (,2 h) versus the three later reperfusion groups combined ($2 h) (6.9 6 11% vs. 3.1 6 12%,
p 5 0.007).
Abbreviations: EF 5 ejection fraction; TIMI 5 Thrombolysis in Myocardial Infarction trials.
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groups combined (p 5 0.03 by log rank test). Survival was very
similar in the three later reperfusion groups with no significant
differences between groups. Using a Cox proportional hazards
regression model to adjust for differences in baseline variables
between early and late reperfusion groups, late reperfusion
($2 h) was a modest predictor of 30-day–plus late cardiac
mortality (relative risk [RR] 1.72, 95% CI 0.96 to 3.11, p 5
0.07) (Table 3). Cardiogenic shock, the inability to restore
TIMI-3 flow, age .70 years and anterior myocardial infarction
were the strongest predictors of 30-day–plus late cardiac
mortality.
Importance of time to reperfusion for recovery of left
ventricular function. Follow-up catheterization was per-
formed in 751 surviving patients. Of these, 606 patients had
acute and follow-up (paired) catheterization data that were
adequate for measurement of left ventricular ejection fractions
at a mean follow-up time of 8.0 6 10.3 months. A comparison
of baseline characteristics in patients with and without paired
ejection fraction data is shown in Table 4. Older patients,
patients with cardiogenic shock and patients with 3-vessel
coronary artery disease were less likely to have follow-up
angiography.
In patients with paired ejection fraction data, acute ejection
fraction was similar in all categories of time to reperfusion
(Table 2). Late ejection fraction was highest in the early
reperfusion group (,2 h) and significantly higher than in the
three later reperfusion groups combined (59.5 6 14% vs.
55.3 6 13.5%, p 5 0.02). Improvement in ejection fraction was
also greatest in the early reperfusion group and relatively
modest after 2 h (6.9 6 11% at ,2 h vs. 3.1 6 12% at $2 h,
p 5 0.007).
Discussion
Previous studies of the importance of time to treatment
with reperfusion therapy. The beneficial effect of reperfusion
therapy for acute myocardial infarction is thought to be due to
myocardial salvage, which results in improved left ventricular
function and better survival (15,16). In concordance with this,
thrombolytic therapy is thought to be most beneficial in the
treatment of acute myocardial infarction when reperfusion is
established early. Data from a number of randomized trials
support this concept (1,4–6). The Fibrinolytic Therapy Trial-
ists Collaborative Group summarized 9 randomized trials with
over 58,000 patients and found a strong relationship between
mortality benefit and time to treatment up to 12 h (4).
Likewise, the Global Utilization of Streptokinase and tPA for
Occluded Coronary Arteries (GUSTO) Trial showed that
hospital mortality progressively increased with increasing time
to treatment (5.3% at #2 h, 5.9% at 2 to 4 h, 8.5% at 4 to 6 h,
and 8.9% at .6 h) (5). However, recent data from the PAMI-2
Trial suggest that the relationship between time to treatment
and mortality may be different with primary PTCA (7). In
1,100 patients treated with primary PTCA, the PAMI group
found that mortality was lowest when patients were treated
very early (,2 h), but that mortality was relatively independent
of time to treatment after 2 h (2.3% at ,2 h, 3.7% at 2 to 4 h,
3.7% at 4 to 6 h and 3.2% at .6 h). (Seventy-three of the
patients in the PAMI-2 Trial were enrolled at our institution
and are included in both studies.)
Major findings of the present study. Our data show that
very early reperfusion (,2 h) with primary PTCA was associ-
ated with a lower 30-day and late mortality compared with
later reperfusion ($2 h). The most interesting and possibly the
most important finding of this study is that 30-day mortality
and late mortality were relatively independent of time to
reperfusion in patients with reperfusion times $2 h. This is in
contrast to data from thrombolytic trials that show mortality
continues to increase with increasing time to treatment up to 6
to 12 h (1,4,5).
Our data also show that early reperfusion (,2 h) was
associated with substantial recovery of left ventricular function
whereas later reperfusion ($2 h) was associated with only
Figure 1. Thirty-day mortality and 30-day–plus late cardiac mortality
versus time to reperfusion. Mortality was significantly less in the early
reperfusion group (,2 h) versus the three later reperfusion groups
combined. Mortality was relatively independent of time to reperfusion
after 2 h. The p values compare the early perfusion group (,2 h) with
the three later reperfusion groups combined ($2 h).
Figure 2. Multivariate predictors of 30-day mortality. The TIMI flow
and cardiogenic shock were the strongest predictors of 30-day mortal-
ity. Late reperfusion ($2 h) was a modest predictor.
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modest recovery of left ventricular function. A partial excep-
tion to this is in patients with reperfusion times .6 h in which
recovery of left ventricular function is somewhat better than
expected. We believe this is related in part to our selection
criteria. Up until 1992, patients were selected for intervention
after 6 h only if they had persistent chest pain or hemodynamic
compromise. We and others have shown previously that pa-
tients who present after 6 h with persistent chest pain have an
increased incidence of collateral flow to the infarct region, and
these patients can have substantial recovery of left ventricular
function after reperfusion (17–20).
Reasons for differences in the results of the present study
and prior thrombolytic trials. There are several possible
reasons that might explain why mortality continues to increase
with increasing time to treatment with thrombolytic therapy,
yet seems to remain relatively constant after 2 h with primary
PTCA. First, data from several trials suggest that successful
reperfusion after thrombolytic therapy is achieved in a smaller
proportion of patients with increasing time to treatment (21–
23, and data from the GUSTO Database, which is on file with
Genentech, South San Francisco, California). The TIMI-1
Trial found that infarct artery patency (TIMI-2 or -3 flow) was
achieved less often with increasing time to treatment after the
administration of intravenous streptokinase (45% at 2 to 4 h,
27% at 4 to 6 h and 17% at .6 h) (21).
Angiographic data from the GUSTO Trial indicate that
TIMI-3 flow is achieved less often with tissue plasminogen
activator (tPA) with increasing time to treatment, although
these differences did not reach statistical significance (63% at
,2 h, 54% at 2 to 4 h and 50% at 4 to 6 h; data from the
GUSTO database). Steg et al. (22) found that patency and
TIMI-3 flow rates decreased with increasing time to treatment
Figure 3. Kaplan–Meier survival curves for 30-
day–plus late cardiac survival for each of four
categories of time to reperfusion. Survival in
the early reperfusion group (,2 h) was signifi-
cantly better than in the three later reperfusion
groups combined (p 5 0.03 by log rank test).
Survival was similar in the three later reperfu-
sion groups, with no significant differences be-
tween groups.
Table 3. Baseline Variables in Patients With and Without Paired Ejection Fraction Data
Patients With Paired
EF Data (n 5 606)
Patients Without Paired
EF Data (n 5 746)
Baseline variable Number (%) Number (%) p Value
Age .70 yrs 103 (17) 191 (26) 0.0002
Age (yrs) (mean 6 SD) 57.7 6 11 61.2 6 12 0.001
Women 164 (27) 228 (31) 0.16
Diabetes 88 (15) 113 (15) 0.75
Prior MI 110 (18) 155 (21) 0.23
Prior CABG 31 (5.1) 32 (4.3) 0.47
Anterior MI 239 (39) 309 (41) 0.46
Cardiogenic shock 24 (4.0) 91 (12) 0.0001
3-Vessel CAD 100 (17) 193 (26) 0.0001
Acute EF ,40%* 104 (17) 114 (19) 0.55
Acute EF (mean 6 SD)* 52.2 6 13 52.4 6 13 0.77
*Includes data on 1,223 subjects, 606 subjects with and 617 subjects without paired EF data. Abbreviations as in Table
1.
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with streptokinase but not with tPA. The RAPID-2 investiga-
tors found that TIMI-3 flow rates decreased with increasing
time to treatment with both reteplase and accelerated tPA
(62% at #6 h vs. 40% at .6 h for reteplace and 47% at #6 h
vs. 35% at .6 h for tPA) (23). In contrast, in this study with
primary PTCA, TIMI-3 flow was achieved in .90% of patients
regardless of time to reperfusion. Because TIMI flow is a
major determinant of hospital mortality with both thrombolytic
therapy and primary PTCA, this may partially explain why
mortality continues to rise with increasing time to treatment
with thrombolytic therapy but remains relatively constant after
2 h with primary PTCA.
Second, mortality due to cardiac rupture appears to be
higher in patients treated with thrombolytic therapy than in
patients not treated, and mortality due to rupture increases
with increasing time to treatment (24–26). If thrombolytic
therapy is given early, the risk of death from myocardial
rupture is reduced, but if thrombolytic therapy is given late, the
risk of death from myocardial rupture is increased (24). In the
Gruppo Italiano per lo Studio della Streptochinasi
nell’Infarcto Miocardico Trial, the mortality rate due to car-
diac rupture with thrombolytic therapy increased progressively
with increasing time to treatment (0.7% at 0 to 3 h, 1.2% at 3
to 6 h, 1.3% at 6 to 9 h and 2.0% at 9 to 12 h) (26). In contrast,
death due to myocardial rupture is very low with primary
PTCA (27,28).
There also is an increasing incidence of hemorrhagic stroke
(often fatal) with increasing time to treatment with thrombo-
lytic therapy. The GUSTO investigators found by univariate
analysis that the incidence of hemorrhagic stroke increased
progressively with increasing time to treatment (0.5% at #2 h,
0.7% at 2 to 4 h, 0.8% at 4 to 6 h and 1.0% at .6 h) (5). The
occurrence of hemorrhagic stroke with primary PTCA is rare
(29).
The combined results of the PAMI, Zwolle and Mayo
Clinic randomized trials have shown improved survival with
PTCA compared to thrombolytic therapy in all time to treat-
ment intervals, but patients presenting late showed the most
survival benefit (30). This is consistent with the observation
that mortality increases with increasing time to treatment with
thrombolytic therapy (for the reasons given above), but is
relatively constant after 2 h with primary angioplasty.
Clinical implications. Our study may have profound impli-
cations regarding the mechanism of benefit of reperfusion
therapy for acute myocardial infarction. The traditional para-
digm regarding the benefit of reperfusion therapy for acute
myocardial infarction is that early reperfusion results in myo-
cardial salvage, which results in improved left ventricular
function and better survival. This paradigm has been expanded
to include benefit of late reperfusion when myocardial salvage
is no longer expected. An open infarct artery, even if opened
too late for myocardial salvage, may result in survival benefit by
preventing ventricular dilatation, promoting electrical stability
and providing a source of collateral flow should occlusion
occur in another coronary artery (15,16). The survival benefit
due to myocardial salvage is felt to be strongly time dependent
and, based on the results of thrombolytic trials, has been
thought to extend to 6 to 12 h. The survival benefit due to late
reperfusion not related to myocardial salvage is felt to be
relatively independent of time to reperfusion. Our data are
consistent with this expanded paradigm, but our data suggest
that the time period for myocardial salvage is relatively short.
Recovery of left ventricular function is very modest after 2 h,
and the predominant mechanism of benefit of reperfusion with
primary PTCA after 2 h may be related to factors other than
myocardial salvage.
Other studies support the concept that the time period for
myocardial salvage is relatively short. Reimer et al. (31) first
described the “wavefront” of myocardial necrosis in the canine
model after coronary occlusion and found that after 2 h of
occlusion little myocardium was viable (30). The Myocardial
Infarction Triage and Intervention investigators (32) found
that patients treated with thrombolytic therapy within 70 min
of symptom onset had a smaller thallium infarct size (4.9% vs.
11.2%, p 5 0.001), greater mean ejection fraction at 30 days
(53% vs. 49%, p 5 0.03) and reduced 30-day mortality (1.2%
vs. 8.7%, p 5 0.04) compared to patients treated at .70 min.
The Mayo Clinic group performed paired sestamibi perfusion
scans prior to reperfusion (with either thrombolytic therapy or
primary PTCA) and at hospital discharge, and found substan-
tial myocardial salvage when reperfusion was established
within 2 h and only modest salvage with reperfusion after 2 h
in the absence of residual blood flow (33).
A second clinical implication of this study relates to
whether withholding thrombolytic therapy to transfer patients
from a community hospital to an interventional facility to
preferentially perform primary PTCA would result in an
unacceptable amount of further myocardial necrosis (34). Our
data suggest that unless infarct artery patency can be restored
within 2 h, the time delay in transferring patients with acute
myocardial infarction to tertiary centers for primary PTCA
Table 4. Multivariate Predictors of 30-Day–Plus Late Cardiac
Mortality by Cox Regression*
Variable
Relative
Risk
95% Confidence
Interval p Value
Cardiogenic shock 4.28 2.71–6.75 , 0.0001
TIMI 0–2 flow 2.78 1.85–4.35 , 0.0001
Age .70 yrs 2.69 1.65–4.38 , 0.0001
Anterior MI 1.89 1.35–2.64 0.0002
Prior MI 1.81 1.22–2.69 0.003
Reperfusion time $2 h 1.72 0.96–3.11 0.07
3-Vessel CAD 1.70 1.18–2.46 0.005
Women 1.61 1.16–2.27 0.004
Acute EF ,40%† 1.58 1.03–2.44 0.04
Diabetes 1.57 1.08–2.29 0.02
Prior CABG 1.36 0.72–2.55 0.34
*Includes data on 1,223 subjects with acute EF data. †Acute EF ,40% is a
very strong univariate predictor of mortality; but because it is significantly
correlated with cardiogenic shock, TIMI 0–2 flow, anterior MI, prior MI and
3-vessel CAD, acute EF ,40% is not as strong a predictor in the multivariate
analysis.
Abbreviations as in Tables 1 and 2.
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may not be prohibitive. If this is true, the proportion of
patients eligible for transfer would be relatively high because
only 12% of patients presented early enough to allow reper-
fusion within 2 h in our study. Two randomized trials have
been designed to answer the questions when and which
patients with acute myocardial infarction should be transferred
to an interventional facility for primary PTCA. The PAMI
group has an ongoing randomized trial (AIR-PAMI) to test
the hypothesis that outcomes in high-risk acute myocardial
infarction patients transferred for primary PTCA, when there
is up to 2 h of transport delay, will be superior to thrombolytic
treatment given at the local hospital (30). Likewise, Ziljstra
and colleagues have a similar trial planned in The Netherlands.
It is hoped the results of these trials will help to answer these
important questions.
Finally, our data reinforce the importance of very early time
to treatment (,2 h) with primary PTCA for acute myocardial
infarction. Mortality in patients in whom patency of the infarct
artery was restored within 2 h was less than one-half the
mortality of patients treated after 2 h. Efforts to reduce patient
delays in contacting the health care system, to provide rapid
transport to hospitals and to establish protocols for rapid
treatment in hospitals should continue with emphasis on
increasing the proportion of patients treated at ,2 h.
Study limitations. Our study has the following limitations.
1. The number of patients in the early reperfusion group is
relatively small, which limits statistical power to detect
differences in outcomes between early and later reperfusion
groups.
2. Our study has follow-up angiography and paired ejection
fraction data in a limited number of patients. There are
some differences in baseline variables between patients with
and without paired follow-up ejection fraction data, so it is
possible that our ejection fraction data may not be repre-
sentative of our entire patient population.
3. Assessment of the time of onset of symptoms of acute
myocardial infarction is often difficult, and this could lead to
errors in determining time to reperfusion. In patients with
TIMI-3 flow on the initial angiogram, the time of the initial
angiogram was used as a time of reperfusion. In these
patients, the actual time of reperfusion may have occurred
much earlier.
4. The TIMI flow in the infarct artery postintervention was
assessed by the operator, and left ventricular ejection
fraction measurements were performed on site rather than
by core lab analysis.
5. Reinfarction or reocclusion after successful reperfusion
could negate the effects of time to treatment on both
mortality and recovery of left ventricular function and could
affect our results. The fact that reinfarction and reocclusion
were distributed similarly across all categories of time to
reperfusion makes it unlikely that this affected our results.
6. Finally, our data represent an observational experience
from one institution. Further multicenter studies will be
needed to confirm our findings.
We thank Gregg W. Stone, MD, at the Cardiovascular Institute, Mountain View,
California, for his thoughtful review and suggestions for this manuscript.
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